Clinical Trials Logo

Clinical Trial Summary

The study purpose is to test the hypothesis that Chronic Phase Chronic Myeloid Leukemia (CP-CML) patients with stable Complete Molecular Response (CMR) who discontinue Dasatinib treatment are able to maintain a sustained remission in the long-term, with undetectable or minimally detectable BCR-ABL residual disease.


Clinical Trial Description

Primary Purpose: Protocol designed to evaluate remission of disease after treatment discontinuation. Treatment re-started if relapse occurs ;


Study Design


Related Conditions & MeSH terms


NCT number NCT01850004
Study type Interventional
Source Bristol-Myers Squibb
Contact
Status Completed
Phase Phase 2
Start date January 22, 2014
Completion date October 8, 2021

See also
  Status Clinical Trial Phase
Completed NCT01593254 - Study of Dasatinib vs Imatinib in Patients With Chronic Myeloid Leukemia (CML) Who Did Not Have Favorable Response to Imatinib Phase 2
Recruiting NCT03610971 - Treatment Free Remission After Combination Therapy With Ruxolitinib Plus Tyrosine Kinase Inhibitors Phase 2
Completed NCT03045120 - Determining Change in Cardiovascular and Metabolic Risks in Patients With Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States
Recruiting NCT03934372 - Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors Phase 1/Phase 2
Completed NCT01702064 - Ruxolitinib in Combination With Nilotinib in Chronic Myeloid Leukemia (CML) Patients Phase 1
Terminated NCT02627677 - A Study Comparing Ponatinib and Nilotinib in Participants With Chronic Myeloid Leukemia Phase 3
Completed NCT01660906 - Phase IV, Open-label, Multicenter Study of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients With Chronic, Low-grade Non-Hematologic Toxicity to Imatinib Phase 4
Completed NCT01933906 - Addition of P1101 to Imatinib Treatment in Patients With Chronic Phase Chronic Myeloid Leukaemia Not Achieving a Complete Molecular Response Phase 1
Completed NCT01914484 - Phase I/II Study of Nilotinib/Ruxolitinb Therapy for TKI Resistant Ph-Leukemia Phase 1/Phase 2